Table 2.
In‐Hospital Cardiac Events of All Study Patients
| fQRS | fQRS (+) | ||
|---|---|---|---|
| Variable | (n = 323) | (n = 91) | P Value |
| Cardiovascular mortality, n (%) | 2 (0.6) | 14 (15.4) | <0.001 |
| Reinfarction, n (%) | 16 (5) | 4 (4.4) | 0.84 |
| Target‐vessel revascularization, n (%) | 17 (5.3) | 4 (4.4) | 0.75 |
| MACE, n (%) | 20 (6.2) | 15 (16.5) | 0.002 |
| Stroke, n (%) | 2 (0.6) | 1 (1.1) | 0.63 |
| Cardiopulmonary resuscitation, n (%) | 6 (1.9) | 15 (16.5) | <0.001 |
| Dialysis, n (%) | 1 (0.3) | 1 (1.1) | 0.33 |
| Advanced heart failure, n (%) | 15 (4.6) | 19 (20.9) | <0.001 |
| Cardiogenic shock, n (%) | 5 (1.5) | 14 (15.4) | <0.001 |
| İnotrop usage, n (%) | 10 (3.1) | 17 (18.7) | <0.001 |
| IABP usage, n (%) | 7 (2.2) | 7 (7.7) | 0.009 |
| Transient pace, n (%) | 6 (1.9) | 6 (6.6) | 0.01 |
| Blood transfusion | 0 (0) | 2 (2.2) | 0.007 |
| Ventilator necessity | 3 (0.9) | 12 (13.2) | <0.001 |
| Acute thrombosis, n (%) | 17 (5.3) | 4 (4.4) | 0.75 |
| Gastrointestinal bleeding, n (%) | 0 (0) | 2 (2.2) | 0.007 |
| LVEF,% (SD) | 49± 8 | 43.9± 10 | <0.001 |
| VT /VF, | 19 (5.9) | 16 (17.6) | 0.01 |
IABP = intra‐aortic balloon pump; LVEF = left ventricular ejection fraction; MACE = major adverse cardiac events (cardiovascular mortality, reinfarction, target‐vessel revascularization); SD = standard deviation; VF = ventricular fibrillation; VT = ventricular tachycardia.